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Abstract: Purpose: To intraindividually compare the efficacy and safety of the SKGEL
® implant versus the T-Flux
® im-
plant in deep sclerectomy. Methods: In a retrospective analysis 17 patients were identified who underwent combined pha-
coemulsification-deep sclerectomy and implantation of SKGEL
® in one eye and T-Flux
® in the contralateral eye. Results: 
In eyes with SKGEL
® the IOP decreased from 20.6+7.3 mm Hg to 14.8+5.3 mm Hg (-5.8 mm Hg or -28.1%), and in eyes 
with T-Flux
® from 19.9+7.2 mm Hg to 14.7+3.3 mm Hg (-5.2 mm Hg or -26.1%, no statistically significant difference, p 
>0.05). Antiglaucoma medications with either implant decreased from initially 2.0+0.8 to 0.3+0.7. A qualified success 
was found in 17/17 eyes with T-Flux
® and in 16/17 eyes with SKGEL
®. Complete success was achieved in 14/17 eyes 
with T-Flux
® and in 13/17 eyes with SKGEL
®. Conclusions: The IOP-lowering effect and safety of SKGEL
® and T-Flux
® 
seem to be comparable. 
INTRODUCTION 
  Non-penetrating glaucoma surgery techniques such as 
deep sclerectomy or viscocanalostomy have been developed 
in recent years. These techniques are presented in a number 
of publications and are now considered to be as effective as 
trabeculectomy in lowering intraocular pressure (IOP), with 
the advantage of being associated with fewer complications 
[1-8]. Especially early complications, e.g. hypotony, hy-
phema and shallow anterior chamber are observed to a much 
lesser extent. 
  A space maintaining implant in the scleral bed seems to 
enhance the IOP-lowering effect of deep sclerectomy [1,9-
11]. Several devices exist which are either absorbable, e.g. 
collagen and reticulated/nonreticulated hyaluronic acid or 
nonabsorbable, e.g. polymethylmethacrylate or Poly-Megma 
hydrogel, and are used with success in deep sclerectomy [12-
18]. The combination of glaucoma and cataract surgery is 
advantageous in patients suffering from both glaucoma and 
senile cataract, avoiding a second operation in the same eye 
[19,20]. Combined surgery is considered safe and effective 
all the more as phacoemulsification alone is presumed to 
lower IOP [21,22], or might improve the effect of deep 
sclerectomy [23]. 
  The aim of this retrospective analysis is to compare the 
IOP-lowering effect of the absorbable SKGEL
® with the 
nonabsorbable T-Flux
® implant. The intraindividual com-
parison limits the influence of individual variations in the 
inflammatory and fibrotic response. All eyes included in the 
analysis received simultaneous phacoemulsification, mini-
mizing the impact of an additional IOP-lowering effect by 
phacoemulsification. 
METHODS 
  For this retrospective study a decided approval of an 
IRB/Ethics Committee was not required. The study was in  
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compliance with the Declaration of Helsinki. From January 
2000 to December 2006, 321 eyes of 189 patients were 
treated with deep sclerectomy and simultaneous phacoemul-
sification in the Augenzentrum (eye centre) Recklinghausen, 
Germany. Out of this number, a total of 17 patients with 34 
eyes were identified who had received the absorbable device 
SKGEL
® 3.5 (Corneal Laboratories, Paris, France) in one 
eye and the nonabsorbable T-Flux
® device (IOLTECH Labo-
ratories, La Rochelle, France) in the contralateral eye. The 
first of these 17 patients had his first eye operated in April 
2002, the last patient his second eye in April 2006, so that 
postoperative IOP was followed for a maximum of 4 years 
and a minimum of 6 months. SKGEL
® 3.5 is a slowly ab-
sorbable implant consisting of a 35 g crosslinked (reticu-
lated) sodium hyaluronate. It is soft, transparent and has the 
shape of an equilateral triangle with a length of 3.5 mm per 
side and a thickness of 0.5 mm. T-Flux
® is a nonabsorbable 
implant made of highly hydrophilic acrylic, a Poly-Megma 
hydrogel. It is non-degradable, biocompatible and resistant 
to fibrosis. It is transparent, flexible and shaped like a T 
where the length of the arms is 4.0 mm, the body height is 
3.4 mm and thickness is from 0.15 to 0.35 mm. It has a tar-
get hole for YAG-laser micropuncture and an additional hole 
for suture fixation of the implant. Assuming that both 
SKGEL
® and T-Flux
® should decrease IOP to the same ex-
tent and that both have the same safety profile, the surgeon 
had no preference for any of the devices to be implanted. 
Indication for surgery was medically uncontrolled primary 
open-angle glaucoma defined by an intraocular pressure 
(IOP) higher than 21 mm Hg under maximal therapy; or pro-
gression of visual field defects in standard automated pe-
rimetry or progression of the optic nerve excavation with or 
without elevated IOP, intolerance to antiglaucomatous drops, 
low patient compliance, as well as a clinically relevant senile 
cataract. Additional criteria to include a patient in the analy-
sis were bilateral combined surgery with a postoperative 
follow-up of at least 6 months and no previously performed 
glaucoma surgery. In case of small, microscopic perforations 
of the trabeculo-Descemet’s membrane during surgery, the 
eye was nevertheless included, as long as the intervention   
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was completed as a deep sclerectomy. Written informed con-
sent was obtained from all patients for both phacoemulsifica-
tion and deep sclerectomy in one session. Prior to consenting 
all patients were informed that a device would be implanted, 
that several kinds of implants exist, and that the type chosen 
depended on the surgeon’s decision. Before surgery, all pa-
tients underwent the following examinations: best corrected 
visual acuity, full slit-lamp examination, fundus examina-
tion, gonioscopy, IOP with Goldmann applanation tonome-
ter, standard automated static white-on-white 30° perimetry 
(Octopus 101, Peridata software, program G2, Haag-Streit, 
Switzerland). All combined operations were performed by 
one surgeon (G.S.). Normally both operations were carried 
out within 3 months, only in one patient the interval was 
longer than one year due to general health problems. Deep 
sclerectomy was made in the superior quadrant. A fornix-
based conjunctival flap was created and the sclera exposed. 
A one-third scleral thickness limbus-based scleral flap of 
approximately 5 x 4 mm in size was marked using a 15° slit 
knife. The flap was dissected up to 1 mm into perilimbal 
clear cornea using a bevel-up crescent knife (1-mm ul-
trasharp knife, Grieshaber, Alcon). This was followed by 
nasal and temporal paracenteses and a clear corneal phacoe-
mulsification in the same site through a 2.8 mm incision un-
der the superficial scleral flap. A foldable acrylic intraocular 
lens was placed in the capsular bag. After IOL placement, 
glaucoma surgery was continued: A triangular smaller flap 
of deep sclera was dissected, leaving only a thin layer of 
scleral fibers over the choroid. The base of the flap was ex-
tended up to 1 mm into clear cornea and down to the De-
scemet’s membrane, unroofing Schlemm’s canal. The deep 
flap was excised with scissors, carefully avoiding tears in the 
Descemet. The inner wall of the Schlemm canal and the jux-
tacanalicular trabecular meshwork was peeled off with 
Utrata forceps. After establishing that aqueous humour per-
colates through the trabecular-Descemet’s membrane, either 
the SKGEL
® or the T-Flux
® implant was placed into the 
scleral bed without a suture. Both arms of the T-Flux
® device 
were carefully inserted into the openings of Schlemm’s ca-
nal. Both the superficial scleral flap and the conjunctiva were 
repositioned and tightly closed with 4-5 single absorbable 
sutures (10x0 Biosorb, Alcon). Postoperatively, all patients 
received topical corticosteroids (prednisolone acetate 1%) 
for at least 6 weeks. Postoperative visits were performed at 
one day, one week, one month, 3 months, 6 months, and de-
pending on the date of surgery, for up to 4 years at least once 
a year. During these visits the following data were collected: 
IOP, best corrected visual acuity, existence of a filtration 
bleb, complications, and need for additional antiglaucoma 
therapy. Standard automated perimetry was carried out every 
6 months. Follow-up was partly done by referring ophthal-
mologists outside the eye centre. At the end of the individual 
observation period, glaucoma surgery was considered a 
complete success when IOP was 21 mm Hg or less without 
antiglaucoma medication and a qualified success when IOP 
was 21 mm Hg or less with or without antiglaucoma treat-
ment. The operation was considered a failure when IOP was 
higher than 21 mm Hg, or when further glaucoma surgery 
was needed or when deterioration of the visual function was 
detected. However, small interventions like needle revision 
or laser goniopunctures would not have been judged as fail-
ures. 
  Unpaired sample two-tailed Student’s t-test was used to 
compare the pre- and postoperative IOP measurements. A p-
value of less than 0.05 was considered statistically signifi-
cant. 
RESULTS 
  Of the 17 patients eligible for case analysis under the 
above mentioned criteria, 3 were male and 14 female with a 
mean age of 77.1 +6.8 years (± standard deviation). The 
overall mean follow-up period was 26.5 +16.4 months in the 
SKGEL
® group and 27.2 +16.0 months in the T-Flux
® 
group, with a range from 6 to 48 months in both groups. The 
mean preoperative IOP was 20.6 +7.3 in the SKGEL
® group 
and 19.9 +7.2 mm Hg in the T-Flux
® group and hence con-
sidered comparable (p >0.05). 
  In both groups the surgical intervention led to a clinically 
relevant result: In the SKGEL
® group the mean preoperative 
IOP decreased to a mean final IOP of 14.8 +5.3 mm Hg (-5.8 
mm Hg or -28.1%), and in the T-Flux
® group to 14.7 +3.3 
mm Hg (-5.2 mm Hg or -26.1%). The difference between 
both groups is statistically not significant (p >0.05). IOP 
results over the full observation period in both groups are 
displayed in Table 1. 
Table 1.  Pre- and Postoperative Intraocular Pressure (IOP) 
 
SKGEL
®  T-Flux
® 
Time 
n IOP  + SD (mm Hg)  n  IOP + SD (mm Hg) 
Preop.  17 20.6  + 7.3  17  19.9 + 7.2 
D 1  16  12.8 + 8.3  17   9.2 + 6.2 
M 1  17  13.9 + 4.2  17  12.8 + 4.3 
M 3  17  12.4 + 4.4  17  12.7 + 3.1 
M 6  17  12.4 + 3.3  17  12.2 + 2.9 
M 12  14  14.6 + 5.0  14  14.4 + 3.3 
M 24  10  14.4 + 5.7  11  15.6 + 2.8 
M 36  8  14.8 + 5.0  8  14.9 + 3.8 
M 48  4  12.3 + 3.8  4  12.8 + 2.9 
 
  Four eyes in each group were followed up for up to four 
years, Three eyes in both groups for at least 6 months. After 
implantation of T-Flux
® or SKGEL
® the curves of IOP 
measurements in both groups were similar in the long-term 
(Fig. 1). 
  The mean number of antiglaucoma medications before 
surgery was 2.0 +0.8 substances in both groups, with a 
minimum of one substance and a maximum of 4 substances. 
With both implants the need for antiglaucoma treatment de-
creased after surgery to 0.3 +0.7 medications at the final 
visit. In other terms, only 3 eyes per group required a per-
manent treatment after surgery, with a maximum of 2 sub-
stances. 2 eyes, one in each group, needed a transitory ther-
apy with betablocker drops for a short time, and no further 
therapy was necessary in these eyes afterwards. 
  At the end of the observation period a qualified success 
(IOP < 21 mm Hg with or without treatment) was found in  
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Fig. (1). Intraocular pressure (IOP) course over time D = day, M = 
months, (number of eyes with T-Flux
® / SKGel
®). 
all 17 eyes with the T-Flux
® device (100%), and in 16 eyes 
with a SKGEL
® implant (94.1%). Complete success (IOP < 
21 mm Hg without treatment) was achieved in 14 T-Flux
® 
eyes (82.4%) and in 13 SKGEL
® eyes (76.5%). One eye in 
the SKGEL
® group has to be considered a failure, as cyclok-
ryocoagulation was inevitable 6 months postoperatively due 
to a strong increase in IOP which was refractory to any 
medical therapy. 
  Complications during glaucoma surgery were: mi-
croperforation of the trabeculo-Descemet’s membrane in 2 
eyes in the T-Flux
® and in one eye in the SKGEL
® group. 
However, in all cases the deep sclerectomy with implanta-
tion of a device could be completed as planned. Apart from 
the usual non-serious intraocular inflammatory signs, in the 
early postoperative phase a massive hyphema was observed 
in one eye with a T-Flux
® implant, possibly due to a hyper-
tensive crisis the patient suffered. The bleeding stopped 
spontaneously and was managed by anterior chamber ir-
rigation. In the other group one eye with SKGEL
® had long-
standing corneal erosion with corneal edema which might 
have been caused by the cataract operation. However, cata-
ract surgery was done in all 34 eyes without any intraopera-
tive complication. In all patients a foldable acrylic posterior 
chamber IOL was implanted. In the observation period no 
other severe complications related to the IOL occurred. 
There was no indication that visual acuity was worse in the 
eyes of these patients than in those who had a simple pha-
coemulsification without a combined deep sclerectomy in 
our centre. In some eyes an opacified posterior capsule was 
treated uneventfully by Nd: YAG laser capsulotomy. Visual 
field results did not reveal clinically relevant deteriorations 
apart from some fluctuation of scotomas, i.e. no increase in 
scotomas were detected in follow-up visual field tests. In one 
eye which was implanted with an SKGEL
® device and that 
had well-controlled IOP without antiglaucomatous therapy, a 
sharp increase in IOP was noted after approximately 6 
months. The rise in IOP was due to neovascular glaucoma 
secondary to a central vein occlusion. Despite full medical 
treatment, the IOP remained uncontrolled with values over 
30 mm Hg, and a decision was made to perform a cyclok-
ryocoagulation, after which the IOP remained at low values 
throughout the following 4 years of observation without any 
treatment. This was the only case where surgical intervention 
was necessary after glaucoma surgery. No laser goniopunc-
ture, no needling or other procedures, e.g. antimetabolite 
injections, were required. Most eyes had no filtering bleb, 
and only a few had a flat or diffuse filtering bleb. 
DISCUSSION 
  The mechanisms by which deep sclerectomy lowers IOP 
are still not fully understood [24]. However, deep sclerec-
tomy has an effect on filtration, hence its success is vulner-
able to scarring and will be positively influenced by the use 
of antimetabolites and theoretically by a device implanted 
within the scleral bed [24-26]. These so-called space main-
tainers are either absorbable implants which degrade within 
several months or nonabsorbable persisting devices 
[2,10,27,28]. Judging from our years of experience with im-
plantation of the devices in glaucoma surgery, we assumed 
that both the absorbable and the nonabsorbable implant 
lower IOP approximately to the same level. Therefore we 
had no preference for a certain device. Also, there were no 
special indications or circumstances where we expected one 
device to perform better than the other. Therefore, over the 
years we accumulated some patients who required glaucoma 
surgery on both eyes and who happened to be implanted with 
both devices. Our retrospective analysis of the patients who 
received SKGEL
® in one eye and T-Flux
® in the contralat-
eral eye bore the opportunity to compare both devices re-
garding their IOP-lowering effect. The intraindividual com-
parison limits the effect of confounding variables, e.g. the 
influence of individual variations in the inflammatory reac-
tion or fibrotic response after deep sclerectomy. Moreover, 
all eyes underwent simultaneous phacoemulsification, pre-
cluding a systematical bias because of a possible IOP-
lowering effect of phacoemulsification. Only very few stud-
ies with an intraindividual control have been performed up to 
now and only few studies have a comparably long follow-up 
with implants in deep sclerectomy. Furthermore, to our 
knowledge there are only two studies comparing the efficacy 
of absorbable versus nonabsorbable implants: Wiermann et 
al. [29] investigated the efficacy of SKGEL
® and T-Flux
® 
implants with and without phacoemulsification in a retro-
spective study of 241 patients over a period of 12 months. 
The results showed no difference in IOP in all 4 groups. 
Mansouri et al. [16] compared a nonabsorbable polymeth-
ylmethacrylate implant versus an absorbable collagen device 
for a mean observation period of 20 months. The effect on 
IOP and the rate of complications were the same in both 
groups. 
  Other studies compared T-Flux
® versus absorbable non-
reticulated hyaluronic acid. Ravinet et al. [17] studied the 
effect of T-Flux
® versus Healon GV
®. During a 2-years fol-
low-up both treatments had fully comparable results. Ates et 
al. [12] compared deep sclerectomy with a T-Flux
® implant 
versus viscocanalostomy: The success rates were similar and 
not significantly better than those of viscocanalostomy. De-
try-Morel [2] in her 5-year long-term study compared deep 
sclerectomy in combination with T-Flux
® / SKGEL
® with 
and without antimetabolite (5-fluorouracil or mitomycine) 
versus Healon GV
® and versus antimetabolite application 
alone. Mean IOP decrease revealed no statistically signifi-
cant difference between the 4 groups. 
  Theoretically, in the long term absorbable implants like 
SKGEL
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The implantation of a nonabsorbable device could create an 
intrascleral space by permanently preventing adhesion be-
tween the scleral flap and the scleral bed. Dahan et al. [30] 
carried out ultrasound biomicroscopy (UBM) investigations 
and confirmed a permanent intrascleral space surrounding 
the T-Flux
® implant. On the other hand, the rationale for the 
absorbable implant is that it can maintain the surgically cre-
ated intrascleral space for several months during the period 
of maximum postoperative inflammation and scarring. It is 
assumed that by the time the implant dissolves, the healing 
process is already completed [11,27,31]. Chiou et al. [31] 
investigated the scleral space by UBM several months after 
implantation of a collagen implant. They observed that the 
implant dissolved slowly, within 6 to 9 months, and was re-
placed by new autologous scleral tissue, yet leaving a tunnel. 
The lifespan of SKGEL
® is not clear but it is estimated to be 
at least as long as for the collagen implant. Marchini and 
associates [25] were unable to determine the lifespan of the 
SKGEL
® as it is nearly undetectable by UBM, in contrast to 
a collagen implant. In glaucoma revision surgery we ex-
tracted a hardly dissolved SKGEL
® device which we had 
placed there more than one year before. 
  In our patients, preoperative mean IOP was lower than in 
some of the studies cited. Ten patients in the SKGEL
® group 
and 12 patients in the T-Flux
® group had IOP meeting the 
criteria of a “qualified” success even before surgery. In these 
cases, indications for surgery were borderline IOP and pro-
gression of glaucoma despite an IOP below or equal to 21 
mm Hg. Of those patients with a preoperative IOP <21 mm 
Hg, there was one patient in each group who still required 
medical glaucoma therapy after surgery. Setting a stricter 
cut-off IOP of <16 mmHg to define success, 10 patients 
(58.8%) in the T-Flux
® group and 9 (52.9%) patients in the 
SKGEL
® group showed a qualified success and 9 (52.9%) 
and 7 patients (41.1%) respectively, a complete success. We 
consider these results as being comparable for both groups. 
  Concerning complications during surgery, we could fin-
ish all interventions as planned; none of them had to be 
transformed to a trabeculectomy despite microperforations of 
the trabeculo-Descemet’s membrane. Postoperatively we did 
not see any iris incarceration. During the postoperative pe-
riod there was no need for goniopuncture or needling, and no 
antifibrotic agents were employed, unlike in other studies 
[2,17]. In one patient a cyclocryocoagulation was performed 
for an uncontrollable rise in IOP. Most of our patients did 
not require postoperative antiglaucoma treatment; in less 
than 20% per group a permanent medical treatment was nec-
essary after surgery. 
  Phacoemulsification can be done simultaneously in glau-
coma patients suffering from additional cataract, avoiding 
the need of a second surgery. However, the contribution of 
lens removal to the IOP-lowering effect of a combined cata-
ract-glaucoma surgery is unclear. Due to the fact that all eyes 
underwent phacoemulsification in our study, all eyes did 
benefit from a possible IOP-lowering effect. A cataract ex-
traction without filtering surgery may result in a decrease of 
IOP in healthy eyes and to a lesser extent in some eyes with 
glaucoma [21,22]. Lens extraction may cause an increase in 
the depth of both the central and the peripheral anterior 
chamber. Accordingly, D’Eliseo et al. [23] observed that 
deep sclerectomy with SKGEL
® combined with pha-
coemulsification achieved better postoperative long-term 
results in IOP control than deep sclerectomy with SKGEL
® 
alone. Furthermore, phacoemulsification seems to lower the 
risk of iris adherence at the site of the Descemetic window, 
thus lowering the risk of an internal filtration block. How-
ever, other authors reported on the absence of statistically 
significant differences of IOP in patients having had non-
penetrating procedures (deep sclerectomy, viscoca-
nalostomy) with or without phacoemulsification, even in the 
long term [9,19,29,32,33]. Wiermann et al. [29] compared 
the efficacy of SKGEL
® versus T-Flux
® with or without 
phacoemulsification and concluded that phacoemulsification 
does not seem to interfere with IOP-lowering final results. 
The majority of authors [9,20,23] used a two-site approach 
when performing phacoemulsification, having a clear corneal 
tunnel situated mostly temporally. We carried out a one-site 
approach phacoemulsification also employed by Wishart et 
al. [19]. The site of the tunnel in combined surgery is proba-
bly without any influence on either the IOP-lowering effect 
or the occurrence of side-effects [29,32,34]. 
  In conclusion, the results of our retrospective analysis 
confirm the results of other studies, in that in open-angle 
glaucoma a deep sclerectomy with implantation of a device 
in combination with phacoemulsification lowers IOP in a 
clinically relevant way over a long period. The effect seems 
to be independent from the absorbable or nonabsorbable 
property of the implant, while the risks of a combined sur-
gery are few when performed by an experienced surgeon. A 
prospective study should confirm our results, ideally adding 
a third group without any implant in order to assess the de 
facto need of a space maintaining implant. 
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